| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/06/2013 | US20130143920 Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia. |
| 06/06/2013 | US20130143919 Pharmaceutical compositions and administrations thereof |
| 06/06/2013 | US20130143918 Solid Forms of (R)-1(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)-N-(1-(2,3-Dihydroxypropyl-6-Fluoro-2-(1-Hydroxy-2-Methylpropan-2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| 06/06/2013 | US20130143917 (2e)-3-phenyl-n-[2,2,2-trifluoro-1-[[8-quinolineamino)thiomethyl]amino]ethyl]-2-acrylamide and pharmaceutical uses thereof |
| 06/06/2013 | US20130143916 Compound libraries made through phosphine-catalyzed annulation/tebbe/diels-alder reactions |
| 06/06/2013 | US20130143913 Prophylactic or therapeutic agent for non-alcoholic steatohepatitis |
| 06/06/2013 | US20130143911 MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors |
| 06/06/2013 | US20130143910 Fructose-1,6-biphosphatases as new targets for diagnosing and treating breast cancer brain metastasis |
| 06/06/2013 | US20130143908 Method for preparing rosuvastatin calcium intermediate |
| 06/06/2013 | US20130143906 Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
| 06/06/2013 | US20130143904 Composition for inhibiting the activity of inositol 1,4,5-triphosphate receptor subtype iii |
| 06/06/2013 | US20130143903 Remedy for migraine headache |
| 06/06/2013 | US20130143902 Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
| 06/06/2013 | US20130143901 Combination of pimavanserin and risperidone for the treatment of psychosis |
| 06/06/2013 | US20130143900 Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
| 06/06/2013 | US20130143899 Compounds and compositions as protein kinase inhibitors |
| 06/06/2013 | US20130143898 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| 06/06/2013 | US20130143897 Oral controlled release pharmaceutical compositions of blonanserin |
| 06/06/2013 | US20130143896 Isoxazolo-quinazolines as modulators of protein kinase activity |
| 06/06/2013 | US20130143891 Methods for Treating Methotrexate-Resistant Disorders with 10-Propargyl-10-Deazaaminopterin |
| 06/06/2013 | US20130143886 Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
| 06/06/2013 | US20130143885 Chemical inducers of neurogenesis |
| 06/06/2013 | US20130143882 Heterocyclic compounds and their uses |
| 06/06/2013 | US20130143880 Positive allosteric modulators of mglur2 |
| 06/06/2013 | US20130143879 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 06/06/2013 | US20130143877 Composition comprising tetracyclic compound |
| 06/06/2013 | US20130143875 Protein Kinase C Inhibitors and Uses Thereof |
| 06/06/2013 | US20130143874 Fused ring pyridine compound |
| 06/06/2013 | US20130143873 Diazoxide For Use In The Treatment Of Amyotrophic Lateral Sclerosis (ALS) |
| 06/06/2013 | US20130143871 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors |
| 06/06/2013 | US20130143869 Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue |
| 06/06/2013 | US20130143868 Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| 06/06/2013 | US20130143867 Acamprosate formulations, methods of using the same, and combinations comprising the same |
| 06/06/2013 | US20130143866 Anticancer combination treatments |
| 06/06/2013 | US20130143862 Certain amino-pyridazines, compositions thereof, and methods of their use |
| 06/06/2013 | US20130143861 Methods for treating atrial fibrillation |
| 06/06/2013 | US20130143860 Guanidine compound |
| 06/06/2013 | US20130143859 Novel prolylcarboxypeptidase inhibitors |
| 06/06/2013 | US20130143858 Compounds and their use as ikach blockers |
| 06/06/2013 | US20130143857 Pharmaceutical compositions of cefditoren pivoxil |
| 06/06/2013 | US20130143856 Novel antibiotic composition comprising flufenamic acid as an active ingredient |
| 06/06/2013 | US20130143855 Method to alleviate diabetic end stage renal disease |
| 06/06/2013 | US20130143852 Inflammatory disease model and method of treatment |
| 06/06/2013 | US20130143851 Testosterone Solutions for the Treatment of Testosterone Deficiency |
| 06/06/2013 | US20130143850 Methods and compositions for stimulating reepithelialisation during wound healing |
| 06/06/2013 | US20130143849 Use of ciclesonide for the treatment of respiratory diseases |
| 06/06/2013 | US20130143848 Use of megestrol acetate for improving heart function and the treatment of heart insufficiency |
| 06/06/2013 | US20130143847 Compositions and methods for treating parkinson's disease and related disorders |
| 06/06/2013 | US20130143846 Polymorphic form of a calcimimetic compound |
| 06/06/2013 | US20130143845 Vitamin d compounds and methods for enhancing muscle strength, and prevention and treatment of disease in human beings |
| 06/06/2013 | US20130143843 Aryl dihydropyridinone and piperidinone mgat2 inhibitors |
| 06/06/2013 | US20130143842 Stable aqueous compositions comprising bioactive creatine species |
| 06/06/2013 | US20130143841 Benzoheterocyclic anti-bacterial agents |
| 06/06/2013 | US20130143840 Heparan sulfate replacement therapy |
| 06/06/2013 | US20130143839 Cystitis treatment with high dose chondroitin sulfate |
| 06/06/2013 | US20130143837 Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate |
| 06/06/2013 | US20130143836 Pharmaceutical composition for treating coagulation disorder hemorrhage and method using the same |
| 06/06/2013 | US20130143834 Cancer Treatment Method |
| 06/06/2013 | US20130143831 Topical pharmaceutical composition comprising flurbiprofen |
| 06/06/2013 | US20130143830 Agents for combating and reducing the irritating action of surfactants in compositions to be applied to the skin for care or cleansing of the face and body |
| 06/06/2013 | US20130143829 Topical Combination Formulations of Macrocyclic Lactones with Synthetic Pyrethroids |
| 06/06/2013 | US20130143827 Tanaproget derivatives, metabolites, and uses thereof |
| 06/06/2013 | US20130143799 Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins |
| 06/06/2013 | US20130143797 Glycoproteins Having Lipid Mobilizing Properties an Therapeutic Uses Thereof |
| 06/06/2013 | US20130143765 Inhibitors of calcium-activated chloride channels |
| 06/06/2013 | US20130142890 Composition and uses for influencing hair growth |
| 06/06/2013 | US20130142888 N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament |
| 06/06/2013 | US20130142887 Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| 06/06/2013 | US20130142882 Methods and compositions for treatment, modification and management of bone cancer pain |
| 06/06/2013 | US20130142877 Pharmaceutical dosage form comprising one or more antiretroviral active ingredients |
| 06/06/2013 | US20130142875 Methods and compositions for treating prostate cancer |
| 06/06/2013 | US20130142874 Pharmaceutical compositions based on diclofenac |
| 06/06/2013 | US20130142872 EMP2: Ethyl-Methyl, di Methyl, tri Methyl Pyruvate Acid Esters: A Tool for Regulating HbA1c and a Riboswitch Activator |
| 06/06/2013 | US20130142871 Oral dosage form of deferasirox |
| 06/06/2013 | US20130142870 Neramexane multiple unit dosage form |
| 06/06/2013 | US20130142869 Compositions Comprising Non Steroidal Anti-inflammatory Drugs and Methods for Use Thereof |
| 06/06/2013 | US20130142867 Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis |
| 06/06/2013 | US20130142865 Fixed dosing of her antibodies |
| 06/06/2013 | US20130142864 In vivo targeting of dendritic cells |
| 06/06/2013 | US20130142851 Compositions Comprising Components Coated With a Liquid Impermeable but Gas Permeable Layer, Use Thereof for Treating Cutaneous and Other Exocrine Gland Diseases |
| 06/06/2013 | US20130142850 Alloplastic injectable dermal filler and methods of use thereof |
| 06/06/2013 | US20130142849 Controlled release formulations of dronedarone |
| 06/06/2013 | US20130142847 S-adenosylmethionine formulations with enhanced bioavailability |
| 06/06/2013 | US20130142845 Use of a combination of an opioid agonist and an opioid antagonist for the treatment of crohn's disease and the symptoms associated with crohn's disease |
| 06/06/2013 | US20130142838 Compositions containing micronized tanaproget prepared by wet granulation |
| 06/06/2013 | US20130142836 Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent |
| 06/06/2013 | US20130142831 Compounds for inflammation and immune-related uses |
| 06/06/2013 | US20130142828 Bacterial ribonucleic acid cell wall compositions and methods of making and using them |
| 06/06/2013 | US20130142827 Induction of immune response |
| 06/06/2013 | US20130142825 Method of preventing and treating inflammatory diseases and disorders with abscisic acid |
| 06/06/2013 | US20130142815 Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase |
| 06/06/2013 | US20130142809 METHODS OF TREATMENT USING AN IFN gamma INHIBITOR |
| 06/06/2013 | US20130142807 Compositions and methods for inhibition of the jak pathway |
| 06/06/2013 | US20130142805 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| 06/06/2013 | US20130142796 Treatment for angiogenic disorders |
| 06/06/2013 | US20130142791 Cyclodextrin nanotechnology for ophthalmic drug delivery |
| 06/06/2013 | US20130142790 Method of Treating Cancer Using a cMET and AXL Inhibitor and an ErbB Inhibitor |
| 06/06/2013 | US20130142784 Method of treating tumor resistant to herceptin or paclitaxel using foxm1 inhibitors and detecting same |
| 06/06/2013 | US20130142781 Peg based hydrogel for peripheral nerve injury applications and compositions and method of use of synthetic hydrogel sealants |
| 06/06/2013 | US20130142778 Compositions for inhibiting gene expression and uses thereof |